Ma Yuan, Yu Sifan, Ni Shuaijian, Zhang Baoxian, Kung Angela Chun Fai, Gao Jin, Lu Aiping, Zhang Ge
Law Sau Fai Institute for Advancing Translational Medicine in Bone and Joint Diseases, School of Chinese Medicine, Hong Kong Baptist University, Kowloon, Hong Kong.
Institute of Integrated Bioinfomedicine and Translational Science, School of Chinese Medicine, Hong Kong Baptist University, Kowloon, Hong Kong.
Front Cell Dev Biol. 2021 Mar 29;9:626910. doi: 10.3389/fcell.2021.626910. eCollection 2021.
Paclitaxel (PTX) has been used for cancer treatment for decades and has become one of the most successful chemotherapeutics in the clinic and financially. However, serious problems with its use still exist, owing to its poor solubility and non-selective toxicity. With respect to these issues, recent advances have addressed the water solubility and tumor specificity related to PTX application. Many measures have been proposed to remedy these limitations by enhancing tumor recognition via ligand-receptor-mediated targeting as well as other associated strategies. In this review, we investigated various kinds of ligands that have emerged as PTX tumor-targeting tools. In particular, this article highlights small molecule-, protein-, and aptamer-functionalized conjugates and nanoparticles (NPs), providing a promising approach for PTX-based individualized treatment prospects.
几十年来，紫杉醇（PTX）一直用于癌症治疗，并且已成为临床上和经济上最成功的化疗药物之一。然而，由于其溶解度差和非选择性毒性，其使用中仍然存在严重问题。针对这些问题，最近的进展已经解决了与PTX应用相关的水溶性和肿瘤特异性问题。已经提出了许多措施来弥补这些限制，通过配体-受体介导的靶向增强肿瘤识别以及其他相关策略。在本综述中，我们研究了作为PTX肿瘤靶向工具出现的各种配体。特别是，本文重点介绍了小分子、蛋白质和适配体功能化的缀合物和纳米颗粒（NPs），为基于PTX的个体化治疗前景提供了一种有前景的方法。
